Benchmark Holdings PLC Notice of Q2 and Interim Results (6197J)
April 28 2022 - 2:02AM
UK Regulatory
TIDMBMK
RNS Number : 6197J
Benchmark Holdings PLC
28 April 2022
Benchmark Holdings plc
("Benchmark" or the "Company")
Notice of Q2 and Interim Results
Webcast for analysts and institutional investors
Equity Development webcast for retail investors
Benchmark Holdings plc (AIM: BMK), the aquaculture health,
advanced nutrition, and genetics business, will announce its Q2 and
Interim results, for the three and six month periods ended 31 March
2022, on Wednesday 18 May 2022.
Webcast for analysts and institutional investors at 9am UK
time
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a webcast for analysts and
institutional investors on that day at 9am UK time. Details will be
sent out separately. If you have any questions, please contact
Charlie Protheroe at MHP Communications on 020 3128 8990 or email
benchmark@mhpc.com.
Equity Development investor presentation for retail investors at
2pm UK time
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a separate webcast for retail
investors and wealth managers at 2pm UK time. The webcast is free
and open to all existing and potential shareholders. Questions can
be submitted during the presentation to be addressed at the
end.
To register for the event, please click here .
A recording of the event will be available afterwards here .
For further information please contact Hannah Crowe / Matt
Evans: 020 7065 2692.
Enquiries
For further information, please contact:
Benchmark Holdings plc Tel: +44 (0) 114 240 9939
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan
Monteith
MHP Communications Tel: 020 3128 8990
Katie Hunt, Reg Hoare, Charlie Protheroe benchmark@mhpc.com
About Benchmark
Benchmark's mission is to enable aquaculture producers to
improve their sustainability and profitability.
We bring together biology and technology, to develop innovative
products which improve yield, quality and animal health and welfare
for our customers. We do this by improving the genetic make-up,
health and nutrition of their stock - from broodstock and hatchery
through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics
and sea lice treatments. Find out more at www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORIRMJTMTBTTPT
(END) Dow Jones Newswires
April 28, 2022 02:02 ET (06:02 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Jul 2023 to Jul 2024